Phase III
The ESMO conference is serving as a post-mortem on the trials that sunk the multi-billion-dollar partnership between Bristol-Myers Squibb and Nektar Therapeutics.
Sanofi and Regeneron presented results from the Phase III PRIME trial that showed Dupixent strongly improves itching and skin lesions in adult patients with prurigo nodularis.
There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.
SpringWorks, Eli Lilly, EMD Serono and Mirati released data ahead of the European Society of Medical Oncology (ESMO) 2022 Meeting in Paris.
Alnylam announced results Thursday from the APOLLO-B study of patisiran that showed improved functional capacity in (ATTR) amyloidosis patients with cardiomyopathy.
Preliminary findings from the NEURO-TTRansform trial show Ionis’ and AstraZeneca’s eplontersen is potentially a safe and effective treatment for patients with amyloidosis.
Gilead, Merck, Daiichi Sankyo, HUTCHMED and BMS previewed data to be presented at the European Society for Medical Oncology Congress 2022, taking place Sept. 9-13.
The FDA approved AstraZeneca’s Imfinzi plus with gemcitabine-cisplatin chemotherapy as the first immunotherapy for adult patients with locally advanced or metastatic biliary tract cancer.
It’s been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.
Sanofi announced FDA approval of Xenpozyme for adult and pediatric patients with the rare genetic disease acid sphingomyelinase deficiency, often referred to as Niemann-Pick disease.
PRESS RELEASES